Evidence map›Paper›PMID 39343957›Full record

ArticleScientific reports2024

Thermothelomyces thermophilus exo- and endo-glucanases as tools for pathogenic E. coli biofilm degradation.

Lorgio Victor Bautista Samaniego, Samuel Luis Scandelau, Caroline Rosa Silva, Sebastião Pratavieira, Vanessa de Oliveira Arnoldi Pellegrini, Andrei Nicoli Gebieluca Dabul, Luís Antônio Esmerino, Mario de Oliveira Neto, Rodrigo Tavanelli Hernandes, Fernando Segato and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lorgio Victor Bautista SamaniegoSao Carlos Institute of Physics, University of Sao Paulo, 1100 João Dagnone Avenue, São Carlos, SP, 13563-120, Brazil.
Samuel Luis ScandelauSao Carlos Institute of Physics, University of Sao Paulo, 1100 João Dagnone Avenue, São Carlos, SP, 13563-120, Brazil.
Caroline Rosa SilvaDepartment of Biotechnology, Genetics and Cell Biology, State University of Maringá, Maringá, Brazil.
Sebastião PratavieiraSao Carlos Institute of Physics, University of Sao Paulo, 1100 João Dagnone Avenue, São Carlos, SP, 13563-120, Brazil.
Vanessa de Oliveira Arnoldi PellegriniSao Carlos Institute of Physics, University of Sao Paulo, 1100 João Dagnone Avenue, São Carlos, SP, 13563-120, Brazil.
Andrei Nicoli Gebieluca DabulSao Carlos Institute of Physics, University of Sao Paulo, 1100 João Dagnone Avenue, São Carlos, SP, 13563-120, Brazil.
Luís Antônio EsmerinoMicrobiology Laboratory, Clinical Analysis Department, Life Sciences and Health Institute, Ponta Grossa State University, Ponta Grossa, Brazil.
Mario de Oliveira NetoInstitute of Biosciences, Sao Paulo State University, District of Rubiao Jr., Botucatu, SP, 18618-970, Brazil.
Rodrigo Tavanelli HernandesInstitute of Biosciences, Sao Paulo State University, District of Rubiao Jr., Botucatu, SP, 18618-970, Brazil.
Fernando SegatoLorena School of Engineering, University of Sao Paulo, Estrada Municipal do Campinho, Lorena, SP, 12602-810, Brazil.
Marcos PileggiEnvironmental Microbiology Laboratory, Structural and Molecular Biology, and Genetics Department, Life Sciences and Health Institute, Ponta Grossa State University, Ponta Grossa, Brazil.
Igor PolikarpovSao Carlos Institute of Physics, University of Sao Paulo, 1100 João Dagnone Avenue, São Carlos, SP, 13563-120, Brazil. ipolikarpov@ifsc.usp.br.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 306852/2021-7 and 440180/2022-8Fundação de Amparo à Pesquisa do Estado de São Paulo 2021/08780-1
6 · The paper itself

Abstract

The escalating prevalence of drug-resistant pathogens not only jeopardizes the effectiveness of existing treatments but also increases the complexity and severity of infectious diseases. Escherichia coli is one the most common pathogens across all healthcare-associated infections. Enzymatic treatment of bacterial biofilms, targeting extracellular polymeric substances (EPS), can be used for EPS degradation and consequent increase in susceptibility of pathogenic bacteria to antibiotics. Here, we characterized three recombinant cellulases from Thermothelomyces thermophilus: a cellobiohydrolase I (TthCel7A), an endoglucanase (TthCel7B), and a cellobiohydrolase II (TthCel6A) as tools for hydrolysis of E. coli and Gluconacetobacter hansenii biofilms. Using a design mixture approach, we optimized the composition of cellulases, enhancing their synergistic activity to degrade the biofilms and significantly reducing the enzymatic dosage. In line with the crystalline and ordered structure of bacterial cellulose, the mixture of exo-glucanases (0.5 TthCel7A:0.5 TthCel6A) is effective in the hydrolysis of G. hansenii biofilm. Meanwhile, a mixture of exo- and endo-glucanases is required for the eradication of E. coli 042 and clinical E. coli biofilms with significantly different proportions of the enzymes (0.56 TthCel7B:0.44 TthCel6A and 0.6 TthCel7A:0.4 TthCel7B, respectively). X-ray diffraction pattern and crystallinity index of E. coli cellulose are comparable to those of carboxymethyl cellulose (CMC) substrate. Our results illustrate the complexity of E. coli biofilms and show that successful hydrolysis is achieved by a specific combination of cellulases, with consistent recurrence of TthCel7B endoglucanase.

Indexed as

BiofilmsEscherichia coliCellulaseHydrolysisHypocrealesCellulase

Identifiers

PMID39343957
PMCPMC11439960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.